FDA delays decision on Moderna’s COVID-19 vaccine in 12-17 age group because of myocarditis concerns: WSJ
FDA delays decision on Moderna’s COVID-19 vaccine in 12-17 age [...]
FDA delays decision on Moderna’s COVID-19 vaccine in 12-17 age [...]
Johnson & Johnson wins FDA panel backing for a second [...]
Bayer, CureVac part ways on COVID-19 vaccine: reports jkeenan Fri, [...]
Despite Merck’s oral COVID-19 drug, antibodies by Regeneron, GSK and [...]
Johnson & Johnson puts talc headache into bankruptcy; plaintiffs will [...]
Fierce Pharma Asia—Takeda’s cell, gene therapy deals; BMS-BeiGene Abraxane brawl [...]
FDA panel backs half-dose Moderna booster for the elderly and [...]
Moderna criticized for COVID-19 vaccine strategy putting once feel-good success [...]
Johnson & Johnson, Moderna COVID-19 vaccines work as intended, FDA [...]
ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis [...]